Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Application of Herbs and Dietary Supplements in ADHD Management

Author(s): Rashmi Mallya*, Beena Naik and Munira Momin

Volume 22, Issue 7, 2023

Published on: 27 August, 2022

Page: [950 - 972] Pages: 23

DOI: 10.2174/1871527321666220720103923

open access plus

conference banner
Abstract

Attention Deficit Hyperactivity Disorder is a neurodevelopmental disorder, which is characterised by a distinct clinical pattern of inattention, hyperactivity as well as impulsivity, which in turn interferes with the day-to-day activities of the affected individual. Although conventional allopathic medications have been found to provide symptomatic relief, they are accompanied by a plethora of side effects that overshadow and outweigh the potential therapeutic benefits. Hence, various alternative approaches in the management of Attention Deficit Hyperactivity Disorder (ADHD) are actively being investigated. Over the past few decades, numerous studies have been initiated and have delved into potential alternative strategies in the treatment and management of ADHD. The primary focus of this article is to discuss the etiology, pathophysiology coupled with a financial background as well as alternative strategies in the treatment and management of ADHD. A review of the literature on the clinical trialson alternative treatment approaches for ADHD showed that, plants and dietary supplements have beneficial effects on ADHD management. But in-depth studies still need to be conducted because the trials reported till now have a smaller sample size and need to be scaled up to get a broader understanding and knowledge of the potential impact of alternative forms of natural treatment on the patient population with ADHD. Also, the manufacturer of the alternative formulations needs to develop effective protocols and processes for the safe, effective, and robust manufacturing of such natural remedies, which fall in line with the expectation of the FDA to gain regulatory clearance for its manufacturing and sale, which can lead to better therapeutic outcomes in patients.

Keywords: Attention deficit hyperactivity disorder, herbal medication, dietary modifications, nutritional supplements, clinical trials, financial impact.

« Previous Next »
[1]
Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord 2010; 2: 241-55.
[http://dx.doi.org/10.1007/s12402-010-0045-8]
[2]
Torgersen T, Gjervan B, Rasmussen K. ADHD in adults: A study of clinical characteristics, impairment and comorbidity. Nord J Psychiatry 2006; 60(1): 38-43.
[http://dx.doi.org/10.1080/08039480500520665] [PMID: 16500798]
[3]
Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry 2017; 17(1): 302.
[http://dx.doi.org/10.1186/s12888-017-1463-3] [PMID: 28830387]
[4]
Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: Expected-cost analysis. Clin Ther 2001; 23(11): 1904-21.
[http://dx.doi.org/10.1016/S0149-2918(00)89086-4] [PMID: 11768842]
[5]
Grif KR, Grieve SM, Clarke S, Williams LM, Korgaonkar MS. Altered gray matter organization in children and adolescents with ADHD : A structural covariance connectome study. Transl Psychiatry 2016; 6(11): e947.
[6]
Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int 2015; 82: 52-68.
[http://dx.doi.org/10.1016/j.neuint.2015.02.001] [PMID: 25684070]
[7]
Mogavero F, Jager A, Glennon JC. Clock genes, ADHD and aggression. Neurosci Biobehav Rev Neurosci 2018; 91: 51-68.
[8]
Schweren LJS, de Zeeuw P, Durston S. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2013; 23(10): 1151-64.
[http://dx.doi.org/10.1016/j.euroneuro.2012.10.014] [PMID: 23165220]
[9]
Available from: https://www.cdc.gov/ncbddd/adhd/data.html
[10]
Shier AC, Reichenbacher T, Ghuman HS, Ghuman JK. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: Clinical strategies. J Cent Nerv Syst Dis 2012; 5: 1-17.
[http://dx.doi.org/10.4137/JCNSD.S6691]
[11]
Liu DY, Shen XM, Yuan FF, et al. The Physiology of BDNF and its relationship with ADHD. Mol Neurobiol 2015; 52(3): 1467-76.
[http://dx.doi.org/10.1007/s12035-014-8956-6] [PMID: 25354496]
[12]
Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014; 48(2): 209-25.
[http://dx.doi.org/10.1177/1060028013510699] [PMID: 24259638]
[13]
Arnsten AFT. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31(11): 2376-83.
[http://dx.doi.org/10.1038/sj.npp.1301164] [PMID: 16855530]
[14]
Lei D, Ma J, Du X, Shen G, Jin X, Gong Q. Microstructural abnormalities in the combined and inattentive subtypes of attention deficit hyperactivity disorder: A diffusion tensor imaging study. Sci Rep 2014; 4: 6875.
[http://dx.doi.org/10.1038/srep06875] [PMID: 25363043]
[15]
Maltezos S, Horder J, Coghlan S, et al. Glutamate/glutamine and neuronal integrity in adults with ADHD : A proton MRS study. Transl Psychiatry 2014; 4(3): e373.
[16]
Brennan AR, Arnsten AF. Neuronal mechanisms underlying attention deficit hyperactivity disorder: The influence of arousal on prefrontal cortical function. Ann N Y Acad Sci 2008; 1129: 236-45.
[http://dx.doi.org/10.1196/annals.1417.007] [PMID: 18591484]
[17]
Curatolo P, D’Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr 2010; 36(1): 79.
[http://dx.doi.org/10.1186/1824-7288-36-79] [PMID: 21176172]
[18]
de Zeeuw P, Zwart F, Schrama R, van Engeland H, Durston S. Prenatal exposure to cigarette smoke or alcohol and cerebellum volume in attention-deficit/hyperactivity disorder and typical development. Transl Psychiatry 2012; 2: e84-9.
[http://dx.doi.org/10.1038/tp.2012.12] [PMID: 22832850]
[19]
Mill J, Petronis A. Pre- and peri-natal environmental risks for attention-deficit hyperactivity disorder (ADHD): The potential role of epigenetic processes in mediating susceptibility. J Child Psychol Psychiatry 2008; 49(10): 1020-30.
[http://dx.doi.org/10.1111/j.1469-7610.2008.01909.x] [PMID: 18492038]
[20]
Goodlett CR, Horn KH, Zhou FC. Alcohol teratogenesis: Mechanisms of damage and strategies for intervention. Exp Biol Med (Maywood) 2005; 230(6): 394-406.
[http://dx.doi.org/10.1177/15353702-0323006-07] [PMID: 15956769]
[21]
Ikonomidou C, Bittigau P, Koch C, Genz K, Stefovska V, Hörster F. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000; 287: 1056-60.
[22]
Hellström-Lindahl E, Gorbounova O, Seiger A, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res Dev Brain Res 1998; 108(1-2): 147-60.
[http://dx.doi.org/10.1016/S0165-3806(98)00046-7] [PMID: 9693793]
[23]
Levitt P. Prenatal effects of drugs of abuse on brain development. Drug Alcohol Depend 1998; 51(1-2): 109-25.
[http://dx.doi.org/10.1016/S0376-8716(98)00070-2] [PMID: 9716934]
[24]
Dwyer JB, McQuown SC, Leslie FM. The dynamic effects of nicotine on the developing brain. Pharmacol Ther 2009; 122(2): 125-39.
[http://dx.doi.org/10.1016/j.pharmthera.2009.02.003] [PMID: 19268688]
[25]
Tiemeier H, Lenroot RK, Greenstein DK, Tran L, Pierson R, Giedd JN. Cerebellum development during childhood and adolescence: A longitudinal morphometric MRI study. Neuroimage 2010; 49(1): 63-70.
[http://dx.doi.org/10.1016/j.neuroimage.2009.08.016] [PMID: 19683586]
[26]
Roza SJ, Verburg BO, Jaddoe VWV, et al. Effects of maternal smoking in pregnancy on prenatal brain development. The Generation R Study. Eur J Neurosci 2007; 25(3): 611-7.
[http://dx.doi.org/10.1111/j.1460-9568.2007.05393.x] [PMID: 17298594]
[27]
Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry 2019; 24(4): 562-75.
[http://dx.doi.org/10.1038/s41380-018-0070-0] [PMID: 29892054]
[28]
Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet 2019; 51(1): 63-75.
[http://dx.doi.org/10.1038/s41588-018-0269-7] [PMID: 30478444]
[29]
Liégeois F, Baldeweg T, Connelly A, Gadian DG, Mishkin M, Vargha-Khadem F. Language fMRI abnormalities associated with FOXP2 gene mutation. Nat Neurosci 2003; 6(11): 1230-7.
[http://dx.doi.org/10.1038/nn1138] [PMID: 14555953]
[30]
Brikell I, Kuja-Halkola R, Larsson H. Heritability of attention-deficit hyperactivity disorder in adults. Am J Med Genet B Neuropsychiatr Genet 2015; 168(6): 406-13.
[http://dx.doi.org/10.1002/ajmg.b.32335] [PMID: 26129777]
[31]
Saha N, Hamad RE, Mohamed S. Inbreeding effects on reproductive outcome in a Sudanese population. Hum Hered 1990; 40(4): 208-12.
[http://dx.doi.org/10.1159/000153932] [PMID: 2379925]
[32]
Thapar A, Holmes J, Poulton K, et al. Genetic basis of attention deficit and hyperactivity. Br J Psychiatry 1999; 174: 105-11.
[http://dx.doi.org/10.1192/bjp.174.2.105] [PMID: 10211163]
[33]
Franke B, Faraone SV, Asherson P, et al. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 2012; 17(10): 960-87.
[http://dx.doi.org/10.1038/mp.2011.138] [PMID: 22105624]
[34]
Freedman R, Hunter SK, Hoffman MC. Prenatal Primary Prevention of mental illness by micronutrient supplements in pregnancy. Am J Psychiatry 2018; 175(7): 607-19.
[http://dx.doi.org/10.1176/appi.ajp.2018.17070836] [PMID: 29558816]
[35]
Wang Y, Hu D, Chen W, Du Xue HY. Prenatal Tobacco Exposure Modulated the Association of Genetic variants with Diagnosed ADHD and its symptom domain in children : A Community Based Case - Control Study. Sci Rep 2019; 9: 4274.
[http://dx.doi.org/10.1038/s41598-019-40850-w]
[36]
Cherry K. 2020. Available from: https://www.verywellmind.com/what-is-the-cerebellum-2794964#:~:text=The
[37]
Gu K, Helga A, Eivind Y. Maternal fever during pregnancy and offspring attention deficit hyperactivity disorder. Mol Psychiatry 2019; 9: 9519.
[38]
Cho SC, Kim BN, Hong YC, et al. Effect of environmental exposure to lead and tobacco smoke on inattentive and hyperactive symptoms and neurocognitive performance in children. J Child Psychol Psychiatry 2010; 51(9): 1050-7.
[http://dx.doi.org/10.1111/j.1469-7610.2010.02250.x] [PMID: 20406335]
[39]
Schuch JB, Genro JP, Bastos CR, Ghisleni G, Tovo-Rodrigues L. The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research. Am J Med Genet B Neuropsychiatr Genet 2018; 177(2): 181-98.
[http://dx.doi.org/10.1002/ajmg.b.32599] [PMID: 28902457]
[40]
Xu X, Breen G, Chen CK, Huang YS, Wu YY, Asherson P. Association study between a polymorphism at the 3′-untranslated region of CLOCK gene and attention deficit hyperactivity disorder. Behav Brain Funct 2010; 6: 48.
[http://dx.doi.org/10.1186/1744-9081-6-48] [PMID: 20704703]
[41]
Carpena MX, Hutz MH, Salatino-Oliveira A, et al. CLOCK polymorphisms in attention-deficit/hyperactivity disorder (ADHD): Further evidence linking sleep and circadian disturbances and ADHD. Genes (Basel) 2019; 10(2): 10.
[http://dx.doi.org/10.3390/genes10020088] [PMID: 30696097]
[42]
Coogan AN, Schenk M, Palm D, et al. Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology 2019; 44(7): 1198-206.
[http://dx.doi.org/10.1038/s41386-019-0327-6] [PMID: 30758328]
[43]
Yoo JH, Sharma V, Kim JW, et al. Prediction of sleep side effects following methylphenidate treatment in ADHD youth. Neuroimage Clin 2020; 26: 102030.
[http://dx.doi.org/10.1016/j.nicl.2019.102030] [PMID: 31711956]
[44]
Brevik EJ, Lundervold AJ, Halmøy A, et al. Prevalence and clinical correlates of insomnia in adults with attention-deficit hyperactivity disorder. Acta Psychiatr Scand 2017; 136(2): 220-7.
[http://dx.doi.org/10.1111/acps.12756] [PMID: 28547881]
[45]
Zhou Rui, Xia Qun, Shen Huaiyun, Yang Xiaoyun, Zhang Yongli. Diagnosis of children’s attention deficit hyperactivity disorder (ADHD) and its association with cytomegalovirus infection with ADHD: A historical review. Int J Clin Exp Med 2015; 8(8): 13969-75.
[46]
Martin J, Walters RK, Demontis D, et al. A genetic investigation of sex bias in the prevalence of attention-deficit/hyperactivity disorder. Biol Psychiatry 2018; 83(12): 1044-53.
[http://dx.doi.org/10.1016/j.biopsych.2017.11.026] [PMID: 29325848]
[47]
Bhalerao S, Munshi R, Nesari T, Shah H. Evaluation of Brāhmī ghṛtam in children suffering from Attention Deficit Hyperactivity Disorder. Anc Sci Life 2013; 33(2): 123-30.
[PMID: 25284947]
[48]
Baron DA, Pato MT, Cyr RL. Treatment of adults with attention-deficit/hyperactivity disorder. J Am Osteopath Assoc 2011; 111(11): 610-4.
[PMID: 22104513]
[49]
Hermens DF, Rowe DL, Gordon E, Williams LM. Integrative neuroscience approach to predict ADHD stimulant response. Expert Rev Neurother 2006; 6(5): 753-63.
[http://dx.doi.org/10.1586/14737175.6.5.753] [PMID: 16734523]
[50]
Senko C, Hulleman CS, Harackiewicz JM. Achievement goal theory at the crossroads: Old controversies, current challenges, and new directions. Educ Psychol 2011; 46: 26-47.
[http://dx.doi.org/10.1080/00461520.2011.538646]
[51]
Weber W. Vander, Stoep A, McCarty L, Rachelle W, Noel S, McClellan J. Hypericum perforatum (St John’s Wort) for attention-deficit/hyperactivity disorder in children and adolescents. Springer Lex Kosmet und Körperpfl 2008; 299: 2633-41.
[52]
Fone KCF, Nutt DJ. Stimulants: Use and abuse in the treatment of attention deficit hyperactivity disorder. Curr Opin Pharmacol 2005; 5(1): 87-93.
[http://dx.doi.org/10.1016/j.coph.2004.10.001] [PMID: 15661631]
[53]
Brown KA, Samuel S, Patel DR. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: A review for practitioners. Transl Pediatr 2018; 7(1): 36-47.
[http://dx.doi.org/10.21037/tp.2017.08.02] [PMID: 29441281]
[54]
Hong SB, Kim JW, Cho SC, Shin MS, Kim BN, Yoo HJ. Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in korean children with attention-deficit/] hyperactivity disorder: Is there an interaction? J Child Adolesc Psychopharmacol 2012; 22(5): 343-52.
[http://dx.doi.org/10.1089/cap.2011.0076] [PMID: 23083021]
[55]
Sinita E, Coghill D. The use of stimulant medications for non-core aspects of ADHD and in other disorders. Neuropharmacology 2014; 87: 161-72.
[http://dx.doi.org/10.1016/j.neuropharm.2014.06.014] [PMID: 24951855]
[56]
Lam AP, Matthies S, Graf E, et al. Long-term effects of multimodal treatment on adult attention-deficit/hyperactivity disorder symptoms: Follow-up analysis of the COMPAS trial. JAMA Netw Open 2019; 2(5): e194980.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.4980] [PMID: 31150084]
[57]
Caye A, Swanson JM, Coghill D, Rohde LA, Caye A. Treatment strategies for ADHD : An evidence-based guide to select optimal treatment. Mol Psychiatry 2019; 24(3): 390-408.
[PMID: 29955166]
[58]
Buitelaar JK. Optimising treatment strategies for ADHD in adolescence to minimise ‘lost in transition’ to adulthood. Epidemiol Psychiatr Sci 2017; 26(5): 448-52.
[http://dx.doi.org/10.1017/S2045796017000154] [PMID: 28413998]
[59]
Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13: 102-16.
[60]
Castells X, Ja R, Bosch R, Nogueira M, Casas M. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 2018(8): CD007813.
[61]
Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005; 3: 5.
[http://dx.doi.org/10.1186/1478-7547-3-5] [PMID: 15946385]
[62]
Guevara J, Lozano P, Wickizer T, Mell L, Gephart H. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108(1): 71-8.
[63]
Altszuler AR, Page TF, Gnagy EM, et al. Financial dependence of young adults with childhood ADHD. J Abnorm Child Psychol 2016; 44(6): 1217-29.
[http://dx.doi.org/10.1007/s10802-015-0093-9] [PMID: 26542688]
[64]
Wang C, Li K, Seo DC, Gaylord S. Use of complementary and alternative medicine in children with ADHD: Results from the 2012 and 2017 National Health Interview Survey. Theor Med 2020; 49: 102352.
[http://dx.doi.org/10.1016/j.ctim.2020.102352] [PMID: 32147074]
[65]
Bader A, Adesman A. Complementary and alternative therapies for children and adolescents with ADHD. Curr Opin Pediatr 2012; 24(6): 760-9.
[http://dx.doi.org/10.1097/MOP.0b013e32835a1a5f] [PMID: 23111680]
[66]
Ni X, Zhang-James Y, Han X, Lei S, Sun J, Zhou R. Traditional Chinese medicine in the treatment of ADHD: A review. Child Adolesc Psychiatr Clin N Am 2014; 23(4): 853-81.
[http://dx.doi.org/10.1016/j.chc.2014.05.011] [PMID: 25220091]
[67]
Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). Ann N Y Acad Sci 2001; 931: 310-41.
[http://dx.doi.org/10.1111/j.1749-6632.2001.tb05788.x] [PMID: 11462750]
[68]
Feucht C, Patel DR. Herbal medicines in pediatric neuropsychiatry. Pediatr Clin North Am 2011; 58(1): 33-54.
[http://dx.doi.org/10.1016/j.pcl.2010.10.006] [PMID: 21281847]
[69]
Lee SH, Park WS, Lim MH. Clinical effects of korean red ginseng on attention deficit hyperactivity disorder in children: An observational study. J Ginseng Res 2011; 35(2): 226-34.
[http://dx.doi.org/10.5142/jgr.2011.35.2.226] [PMID: 23717065]
[70]
Sawni A. Attention-deficit/hyperactivity disorder and complementary/alternative medicine. Adolesc Med State Art Rev 2008; 19(2): 313-26. xi.
[http://dx.doi.org/10.1542/9781581104035-attention] [PMID: 18822835]
[71]
Ross SM. Valerian root and lemon balm extracts: A phytomedicine compound improves symptoms of hyperactivity, attention deficits, and impulsivity in children. Holist Nurs Pract 2015; 29(6): 391-5.
[http://dx.doi.org/10.1097/HNP.0000000000000118] [PMID: 26465629]
[72]
Nam Y, Shin EJ, Shin SW, et al. YY162 prevents ADHD-like behavioral side effects and cytotoxicity induced by Aroclor1254 via interactive signaling between antioxidant potential, BDNF/TrkB, DAT and NET. Food Chem Toxicol 2014; 65: 280-92.
[http://dx.doi.org/10.1016/j.fct.2013.12.046] [PMID: 24394491]
[73]
Bloch MH, Mulqueen J. Nutritional supplements for the treatment of ADHD. Child Adolesc Psychiatr Clin N Am 2014; 23(4): 883-97.
[http://dx.doi.org/10.1016/j.chc.2014.05.002] [PMID: 25220092]
[74]
Shakibaei F, Radmanesh M, Salari E, Mahaki B. Complementary Therapies in Clinical Practice Ginkgo biloba in the treatment of attention-de fi cit/hyperactivity disorder in children and adolescents. A randomized. Complement Ther Clin Pract 2015; 21: 61-7.
[http://dx.doi.org/10.1016/j.ctcp.2015.04.001] [PMID: 25925875]
[75]
Zuo W, Yan F, Zhang B, Li J, Mei D. Advances in the studies of Ginkgo biloba leaves extract on aging-related diseases. Aging Dis 2017; 8(6): 812-26.
[http://dx.doi.org/10.14336/AD.2017.0615] [PMID: 29344418]
[76]
Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: Mechanisms and clinical indications. Arch Phys Med Rehabil 2000; 81(5): 668-78.
[http://dx.doi.org/10.1016/S0003-9993(00)90052-2] [PMID: 10807109]
[77]
Anonymous . EGb 761: Ginkgo biloba extract, Ginkor. Drugs R D 2003; 4(3): 188-93.
[http://dx.doi.org/10.2165/00126839-200304030-00009] [PMID: 12757407]
[78]
Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: Chemistry, efficacy, safety, and uses. J Food Sci 2008; 73(1): R14-9.
[http://dx.doi.org/10.1111/j.1750-3841.2007.00597.x] [PMID: 18211362]
[79]
Trebatická J. Psychiatric disorders and polyphenols: Can they be helpful in therapy? Oxid Med Cell Longev 2015; 2015: 248529.
[80]
Niederhofer H. Ginkgo biloba treating patients with attention-deficit disorder. Phytother Res 2010; 24(1): 26-7.
[http://dx.doi.org/10.1002/ptr.2854] [PMID: 19441138]
[81]
Kennedy DO, Haskell CF, Mauri PL, Scholey AB. Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine. Hum Psychopharmacol 2007; 22(4): 199-210.
[http://dx.doi.org/10.1002/hup.837] [PMID: 17457961]
[82]
Yarnell E. Herbs for attention-deficit/hyperactivity disorder. Altern Complement Ther 2018; 24: 133-9.
[http://dx.doi.org/10.1089/act.2018.29168.eya]
[83]
Salehi B, Imani R, Reza M, et al. Progress in neuro-psychopharmacology & biological psychiatry Ginkgo biloba for attention-deficit/hyperactivity Disorder in children and adolescents : A double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 76-80.
[http://dx.doi.org/10.1016/j.pnpbp.2009.09.026] [PMID: 19815048]
[84]
Kean J D, Kaufman J, Lomas J, et al. A randomized controlled trial investigating the effects of a special extract of Bacopa monnieri (CDRI 08) on hyperactivity and inattention in male children and adolescents : BACHI study protocol (ANZCTRN12612000827831). 2015; 9931-45.
[85]
Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer’s disease. Ann Neurosci 2017; 24(2): 111-22.
[http://dx.doi.org/10.1159/000475900] [PMID: 28588366]
[86]
Dutta B, Barua TK, Ray J, et al. A study of evaluation of safety and efficacy of memomet, a multi herbal formulation (memomet) in the treatment of behavioural disorder in children. Int J Res Pharm Sci 2012; 3: 282-6.
[87]
Mitra-Ganguli T, Kalita S, Bhushan S, et al. A randomized, double-blind study assessing changes in cognitive function in Indian school children receiving a combination of Bacopa monnieri and micronutrient supplementation vs. placebo. Front Pharmacol 2017; 8: 678.
[http://dx.doi.org/10.3389/fphar.2017.00678] [PMID: 29204115]
[88]
Motaharifard MS, Effatpanah M, Karimi M, et al. Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial. Complement Ther Clin Pract 2019; 36: 170-5.
[http://dx.doi.org/10.1016/j.ctcp.2019.07.008] [PMID: 31383435]
[89]
Dave UP, Dingankar SR, Saxena VS, et al. An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children. Adv Mind Body Med 2014; 28(2): 10-5.
[PMID: 24682000]
[90]
Razlog R, Pellow J, White SJN. A pilot study on the efficacy of Valeriana officinalis mother tincture and Valeriana officinalis 3x in the treatment of attention deficit hyperactivity disorder. Heal SA Gesondheid 2012; 17: 1-7.
[http://dx.doi.org/10.4102/hsag.v17i1.603]
[91]
Ahn J, Ahn HS, Cheong JH, Dela Peña I. Natural product-derived treatments for attention-deficit/hyperactivity disorder: Safety, efficacy, and therapeutic potential of combination therapy. Neural Plast 2016; 2016: 1320423.
[92]
Gromball J, Beschorner F, Wantzen C, Paulsen U, Burkart M. Hyperactivity, concentration difficulties and impulsiveness improve during seven weeks’ treatment with valerian root and lemon balm extracts in primary school children. Phytomedicine 2014; 21(8-9): 1098-103.
[http://dx.doi.org/10.1016/j.phymed.2014.04.004] [PMID: 24837472]
[93]
Hou W, Wang Y, Zheng P, Cui R. Effects of ginseng on neurological disorders. Front Cell Neurosci 2020; 14: 55.
[http://dx.doi.org/10.3389/fncel.2020.00055] [PMID: 32265659]
[94]
Vol JGR, Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. J Ginseng Res 2013; 37: 8-29.
[95]
Jovanovski E. Lea-Duvnjak-Smircic , Komishon A, et al. Vascular effects of combined enriched Korean Red ginseng (Panax ginseng) and American ginseng (Panax quinquefolius) administration in individuals with hypertension and type 2 diabetes: A randomized controlled trial. Complement Ther Med 2020; 49: 102338.
[http://dx.doi.org/10.1016/j.ctim.2020.102338] [PMID: 32147072]
[96]
Benishin CG. Actions of ginsenoside Rb1 on choline uptake in central cholinergic nerve endings. Neurochem Int 1992; 21(1): 1-5.
[http://dx.doi.org/10.1016/0197-0186(92)90061-U] [PMID: 1338897]
[97]
Niederhofer H. Panax ginseng may improve some symptoms of attention-deficit hyperactivity disorder. J Diet Suppl 2009; 6: 22-7.
[98]
Ko H, Kim I, Kim J, et al. Effects of Korean red ginseng extract on behavior in children with symptoms of inattention and hyperactivity/impulsivity. J Child Adolesc Psychopharmacol 2014; 24: 501-8.
[99]
Lyon MR, Cline JC, Zepetnek JT, et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: A pilot study. J Psychiatry Neurosci 2001; 26(3): 221-8.
[100]
Puttarak P, Dilokthornsakul P, Saokaew S, et al. Effects of Centella asiatica (L.) Urb. on cognitive function and mood related outcomes: A systematic review and meta-analysis. Sci Rep 2017; 7: 1-12.
[101]
Smaga I, Niedzielska E, Gawlik M, et al. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacol Rep 2015; 67(3): 569-80.
[http://dx.doi.org/10.1016/j.pharep.2014.12.015] [PMID: 25933971]
[102]
Shinomol GK. Muralidhara, Bharath MM. Exploring the role of “Brahmi” (Bacopa monnieri and Centella asiatica) in brain function and therapy. Recent Pat Endocr Metab Immune Drug Discov 2011; 5(1): 33-49.
[http://dx.doi.org/10.2174/187221411794351833] [PMID: 22074576]
[103]
Veerendra Kumar MH, Gupta YK. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer’s disease in rats. Clin Exp Pharmacol Physiol 2003; 30(5-6): 336-42.
[http://dx.doi.org/10.1046/j.1440-1681.2003.03842.x] [PMID: 12859423]
[104]
Katz M, Levine AA, Kol-Degani H, Kav-Venaki L. A compound herbal preparation (CHP) in the treatment of children with ADHD: A randomized controlled trial. J Atten Disord 2010; 14(3): 281-91.
[http://dx.doi.org/10.1177/1087054709356388] [PMID: 20228219]
[105]
Akhondzadeh S, Gerbarg PL, Brown RP. Nutrients for prevention and treatment of mental health disorders. Psychiatr Clin North Am 2013; 36: 25-36.
[106]
Alcantara J, Davis J. The chiropractic care of children with attention-deficit/hyperactivity disorder: A retrospective case series. Explore (NY) 2010; 6(3): 173-82.
[http://dx.doi.org/10.1016/j.explore.2010.02.001] [PMID: 20451152]
[107]
Stevens AJ, Purcell RV, Darling KA, Eggleston MJF, Kennedy MA, Rucklidge JJ. Human gut microbiome changes during a 10 week randomised control trial for micronutrient supplementation in children with attention deficit hyperactivity disorder. Sci Rep 2019; 9: 10128.
[108]
Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention deficit hypersensitivity disorder. A preliminary report. Neuropsychobiology 1997; 35: 178-80.
[http://dx.doi.org/10.1159/000119341] [PMID: 9246217]
[109]
Baumeister J, Barthel T, Geiss KR, Weiss M. Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress. Nutr Neurosci 2008; 11(3): 103-10.
[http://dx.doi.org/10.1179/147683008X301478] [PMID: 18616866]
[110]
Kim HY, Huang BX, Spector AA. Phosphatidylserine in the brain: Metabolism and function. Prog Lipid Res 2014; 56: 1-18.
[http://dx.doi.org/10.1016/j.plipres.2014.06.002] [PMID: 24992464]
[111]
Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: A randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet 2014; 27 (Suppl. 2): 284-91.
[http://dx.doi.org/10.1111/jhn.12090] [PMID: 23495677]
[112]
Kidd PM. Phosphatidylserine; Membrane nutrient for memory. A clinical and mechanistic assessment. Altern Med Rev 1996; 1: 70-84.
[113]
Panel E, Nda A. Opinion on the substantiation of health claims related to phosphatidyl serine (ID 552, 711, 734, 1632, 1927) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2010; 8(10): 1749.
[114]
Hellhammer J, Vogt D, Franz N, Freitas U, Rutenberg D. A soy-based phosphatidylserine/phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: A randomized, placebo-controlled study. Lipids Health Dis 2014; 13: 121.
[http://dx.doi.org/10.1186/1476-511X-13-121] [PMID: 25081826]
[115]
Jäger R, Bökenkamp D. Cargill texturizing solutions Deutschland GmbH and Co KG, assignee. Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS). United States Patent US 8,129,360, 2012.
[116]
Manor I, Rozen S, Manor Y, Pelled D, Weizman A. S01-03 Efficacy and safety of N-3 phosphatidylserine in children with attention deficit and hyperactivity disorder (ADHD). Eur Psychiatry 2009; 24: S12.
[http://dx.doi.org/10.1016/S0924-9338(09)70245-7]
[117]
El Baza F, AlShahawi HA, Zahra S, AbdelHakim RA. Magnesium supplementation in children with attention deficit hyperactivity disorder. Egypt J Med Hum Genet 2016; 17: 63-70.
[http://dx.doi.org/10.1016/j.ejmhg.2015.05.008]
[118]
Mousain-Bosc CS. Magnesium in the central nervous system. Adelaide (AU): University of Adelaide Press; 2011.
[119]
Robberecht H, Verlaet AAJ, Breynaert A, De Bruyne T, Hermans N. Magnesium, Iron, Zinc, copper and selenium status in attention-deficit/hyperactivity disorder (ADHD). Molecules 2020; 25(19): 25.
[http://dx.doi.org/10.3390/molecules25194440] [PMID: 32992575]
[120]
Huss M, Völp A, Stauss-Grabo M. Supplementation of polyunsaturated fatty acids, magnesium and zinc in children seeking medical advice for attention-deficit/hyperactivity problems-an observational cohort study. Lipids Health Dis 2010; 9: 105.
[http://dx.doi.org/10.1186/1476-511X-9-105] [PMID: 20868469]
[121]
Mahmoud MM, El-Mazary A-AM, Maher RM, Saber MM. Zinc, ferritin, magnesium and copper in a group of Egyptian children with attention deficit hyperactivity disorder. Ital J Pediatr 2011; 37: 60.
[http://dx.doi.org/10.1186/1824-7288-37-60] [PMID: 22206662]
[122]
Hemamy M, Pahlavani N, Amanollahi A, et al. The effect of vitamin D and magnesium supplementation on the mental health status of attention-deficit hyperactive children: A randomized controlled trial. BMC Pediatr 2021; 21(1): 178.
[http://dx.doi.org/10.1186/s12887-021-02631-1] [PMID: 33865361]
[123]
Huang A, Seshadri K, Matthews TA, Ostfeld BM. Parental perspectives on use, benefits, and physician knowledge of complementary and alternative medicine in children with autistic disorder and attention-deficit/hyperactivity disorder. J Altern Complement Med 2013; 19(9): 746-50.
[http://dx.doi.org/10.1089/acm.2012.0640] [PMID: 23621389]
[124]
Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron 2010; 65(2): 165-77.
[http://dx.doi.org/10.1016/j.neuron.2009.12.026] [PMID: 20152124]
[125]
Lepping P, Huber M. Role of Zinc in the pathogenesis of attention-deficit hyperactivity disorder implications for research and treatment. CNS Drugs 2010; 24: 721-8.
[126]
Yorbik O, Ozdag MF, Olgun A, Senol MG, Bek S, Akman S. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 662-7.
[http://dx.doi.org/10.1016/j.pnpbp.2007.11.009]
[127]
Arnold LE, Disilvestro RA, Ph D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol 2011; 21: 1-19.
[128]
Villagomez A, Ramtekkar U. Iron, Magnesium, Vitamin D, and Zinc deficiencies in children presenting with symptoms of attention-deficit/hyperactivity disorder. Children (Basel) 2014; 1(3): 261-79.
[http://dx.doi.org/10.3390/children1030261] [PMID: 27417479]
[129]
Tippairote T, Temviriyanukul P, Benjapong W, Trachootham D. Hair Zinc and severity of symptoms are increased in children with attention deficit and hyperactivity disorder: A hair multi-element profile study. Trace Elem Res 2017; 179(2): 185-94.
[http://dx.doi.org/10.1007/s12011-017-0978-2] [PMID: 28251481]
[130]
Dodig-Curković K, Dovhanj J, Curković M, Dodig-Radić J, Degmecić D. The role of Zinc in the treatment of hyperactivity disorder in children. Acta Med Croatica 2009; 63(4): 307-13.
[PMID: 20034331]
[131]
Zamora J, Velásquez A, Troncoso L, Barra P, Guajardo K, Castillo-Duran C. Zinc in the therapy of the attention-deficit/] hyperactivity disorder in children. A preliminar randomized controlled trial. Arch Latinoam Nutr 2011; 61(3): 242-6.
[PMID: 22696891]
[132]
Hurt EA, Arnold LE. Dietary and nutritional treatments for attention-deficit/hyperactivity disorder: Current research support and recommendations for practitioners. Curr Psychiatry Rep 2011; 13(5): 323-32.
[133]
Pelsser LM, van Steijn DJ, Frankena K, Toorman J, Buitelaar JK, Rommelse NN. A randomized controlled pilot study into the effects of a restricted elimination diet on family structure in families with ADHD and ODD. Child Adolesc Ment Health 2013; 18(1): 39-45.
[http://dx.doi.org/10.1111/j.1475-3588.2012.00652.x] [PMID: 32847264]
[134]
Gillies D, Sinn JKH, Lad SS, Leach MJ, Ross MJ. A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder. Dement Neuropsychol 2021; 15(4): 421-7.
[135]
Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(1): 181-90.
[http://dx.doi.org/10.1016/j.pnpbp.2003.09.034] [PMID: 14687872]
[136]
Wallace DF. The regulation of iron absorption and homeostasis. Clin Biochem Rev 2016; 37(2): 51-62.
[PMID: 28303071]
[137]
Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014; 19(2): 164-74.
[PMID: 24778671]
[138]
Reinert A, Morawski M, Seeger J, Arendt T, Reinert T. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations. BMC Neurosci 2019; 20(1): 25.
[http://dx.doi.org/10.1186/s12868-019-0507-7] [PMID: 31142282]
[139]
Hariri M, Azadbakht L. Magnesium, Iron, and Zinc supplementation for the treatment of attention deficit hyperactivity disorder: A systematic review on the recent literature. Int J Prev Med 2015; 6: 83.
[http://dx.doi.org/10.4103/2008-7802.164313] [PMID: 26445630]
[140]
Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008; 38(1): 20-6.
[http://dx.doi.org/10.1016/j.pediatrneurol.2007.08.014] [PMID: 18054688]
[141]
Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/] hyperactivity disorder. Child Adolesc Psychopharmacol 2010; 20(6): 495-502.
[http://dx.doi.org/10.1089/cap.2010.0053] [PMID: 21186968]
[142]
Arnold LE, Amato A, Bozzolo H, et al. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: A multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2007; 17(6): 791-802.
[http://dx.doi.org/10.1089/cap.2007.018] [PMID: 18315451]
[143]
Fielding R, Riede L, Lugo JP, Bellamine A. L-carnitine supplementation in recovery after exercise. Nutrients 2018; 10(3): 1-17.
[http://dx.doi.org/10.3390/nu10030349] [PMID: 29534031]
[144]
Abbasi S-H, Heidari S, Mohammadi M-R, Tabrizi M, Ghaleiha A, Akhondzadeh S. Acetyl-L-Carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: A placebo-controlled trial. Child Psychiatry Hum Dev 2011; 42: 367-75.
[145]
Inano A, Sai Y, Nikaido H, et al. Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Dispos 2003; 24(8): 357-65.
[http://dx.doi.org/10.1002/bdd.371] [PMID: 14595704]
[146]
Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2002; 67(1): 33-8.
[http://dx.doi.org/10.1054/plef.2002.0378] [PMID: 12213433]
[147]
Adriani W, Rea M, Baviera M, et al. Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology (Berl) 2004; 176(3-4): 296-304.
[http://dx.doi.org/10.1007/s00213-004-1892-9] [PMID: 15138763]
[148]
Landaas ET, Aarsland TIM, Ulvik A, Halmøy A, Ueland PM, Haavik J. Vitamin levels in adults with ADHD. BJPsych Open 2016; 2(6): 377-84.
[http://dx.doi.org/10.1192/bjpo.bp.116.003491] [PMID: 27990293]
[149]
Gironés-Vilaplana A, Villanõ D, Marhuenda J, Moreno DA, Garciá-Viguera C. Vitamins In book Nutraceutical and Functional Food Components. Intechopen 2017; pp. 159-201.
[150]
Dolina S, Margalit D, Malitsky S, Rabinkov A. Attention-deficit hyperactivity disorder (ADHD) as a pyridoxine-dependent condition: Urinary diagnostic biomarkers. Med Hypotheses 2014; 82(1): 111-6.
[http://dx.doi.org/10.1016/j.mehy.2013.11.018] [PMID: 24321736]
[151]
Mousain-Bosc M, Roche M, Polge A, Pradal-Prat D, Rapin J, Bali JP. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. Magnes Res 2006; 19(1): 46-52.
[PMID: 16846100]
[152]
Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J 2015; 29(6): 2207-22.
[http://dx.doi.org/10.1096/fj.14-268342] [PMID: 25713056]
[153]
Goksugur SB, Tufan AE, Semiz M, et al. Vitamin D status in children with attention-deficit-hyperactivity disorder. Pediatr Int 2014; 56(4): 515-9.
[http://dx.doi.org/10.1111/ped.12286] [PMID: 24417979]
[154]
Morales E, Julvez J, Torrent M, et al. Vitamin D in pregnancy and attention deficit hyperactivity disorder-like symptoms in childhood. Epidemiology 2015; 26(4): 458-65.
[http://dx.doi.org/10.1097/EDE.0000000000000292] [PMID: 25867115]
[155]
Mohammadpour N, Jazayeri S, Tehrani-Doost M, et al. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial. Nutr Neurosci 2018; 21(3): 202-9.
[http://dx.doi.org/10.1080/1028415X.2016.1262097] [PMID: 27924679]
[156]
Cornish S, Mehl-Madrona L. The role of vitamins and minerals in psychiatry. Integr Med Insights 2008; 3: 33-42.
[http://dx.doi.org/10.4137/117863370800300003] [PMID: 21614157]
[157]
Yoon SY, dela Peña I, Kim SM, et al. Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro. Arch Pharm Res 2013; 36(1): 134-40.
[http://dx.doi.org/10.1007/s12272-013-0009-6] [PMID: 23371806]
[158]
Lu L, Guo Q, Zhao L, Oroxylin A. Overview of Oroxylin A: A promising flavonoid compound. Phytother Res 2016; 30(11): 1765-74.
[http://dx.doi.org/10.1002/ptr.5694] [PMID: 27539056]
[159]
Pusceddu MM, Kelly P, Stanton C, Cryan JF, Dinan TG. N-3 polyunsaturated fatty acids through the lifespan: Implication for psychopathology. Int J Neuropsychopharmacol 2016; 19(12): 19.
[http://dx.doi.org/10.1093/ijnp/pyw078] [PMID: 27608809]
[160]
Millichap JG, Yee MM. The diet factor in attention-deficit/] hyperactivity disorder. Pediatrics 2012; 129(2): 330-7.
[http://dx.doi.org/10.1542/peds.2011-2199] [PMID: 22232312]
[161]
Nigg JT, Holton K. Restriction and elimination diets in ADHD treatment. Child Adolesc Psychiatr Clin N Am 2014; 23(4): 937-53.
[http://dx.doi.org/10.1016/j.chc.2014.05.010] [PMID: 25220094]
[162]
Wentz E, Björk A, Dahlgren J. Is there an overlap between eating disorders and neurodevelopmental disorders in children with obesity? Nutrients 2019; 11(10): E2496.
[http://dx.doi.org/10.3390/nu11102496] [PMID: 31627342]
[163]
Sensitivity NG. Healthy nutritional habits should be encouraged in all children independently of the existence or non-existence of neurodevelopmental disorders Truths, Myths and Needs of Special Diets: Attention-Deficit/Hyperactivity Disorder, Autism, Non-Celiac. Ann Nutr Metab 2016; 68: 43-50.
[164]
Stevenson J, Buitelaar J, Cortese S, et al. Research review: The role of diet in the treatment of attention-deficit/hyperactivity disorder-an appraisal of the evidence on efficacy and recommendations on the design of future studies. J Child Psychol Psychiatry 2014; 55(5): 416-27.
[http://dx.doi.org/10.1111/jcpp.12215] [PMID: 24552603]
[165]
Behdani F, Hebrani P, Naseraee A, Haghighi MB, Akhavanrezayat A. Does omega-3 supplement enhance the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients? J Res Med Sci 2013; 18(8): 653-8.
[PMID: 24379840]
[166]
Derbyshire E. Do Omega-3/6 fatty acids have a therapeutic role in children and young people with ADHD? J Lipids 2017; 2017: 6285218.
[http://dx.doi.org/10.1155/2017/6285218] [PMID: 28951787]
[167]
Joshi K, Lad S, Kale M, et al. Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006; 74(1): 17-21.
[http://dx.doi.org/10.1016/j.plefa.2005.10.001] [PMID: 16314082]

Rights & Permissions Print Cite
Article Metrics
7
© 2024 Bentham Science Publishers | Privacy Policy